The Company plans to initiate a Phase 3 program evaluating INCA033989 in essential thrombocythemia (ET) patients with all types of CALR mutations in mid-2026, following alignment with regulators ...
QIAGEN to create a multimodal panel using next-generation sequencing (NGS) technology for detecting clinically relevant gene alterations in hematological malignancies Companion diagnostic to identify ...
WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq:INCY) today announced the first clinical data from two studies evaluating the safety, tolerability and efficacy of INCA033989, a novel, first in ...
Preliminary findings from 51 evaluable ET patients showed treatment with INCA033989 monotherapy demonstrated rapid and durable normalization of platelet counts. The Food and Drug Administration (FDA) ...
Incyte INCY announced that the FDA has granted the Breakthrough Therapy designation to its investigational, first-in-class, mutCALR-targeted monoclonal antibody, INCA033989, to treat patients with ...
MPN-U patients exhibit lower platelet counts and higher venous thrombosis rates compared to ET, with thrombosis often occurring at atypical sites. Genetic analysis shows JAK2 mutations are more common ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results